Marker Therapeutics, Inc.

MRKR: Is Marker Therapeutics, Inc. Halal?

Marker Therapeutics, Inc.

NASDAQHealthcareUS

$1.52

+1.33%

Market Cap: 25.3M

Compliance Status

Not Halal

Screened on Aug 26, 2026 · AAOIFI Standard 21

F

Non-Compliant

0Score

Is Marker Therapeutics, Inc. (MRKR) halal? Not Halal. Based on AAOIFI screening, Marker Therapeutics, Inc. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.0% of 30.0% limit

What this means for you

Most scholars advise not holding MRKR

It does not pass AAOIFI Shariah screening.

See halal alternatives from the same sector further down this page

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 26, 2026

Compliance History

Not Halal, unchanged since Aug 2026.

No status changes recorded since we began tracking.

Tracked since Aug 2026. Updates automatically on each re-screen.

Fiscal: Q1 2026Data source: EDGAR
Free · No credit card required

Track MRKR and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Marker Therapeutics, Inc. (MRKR) halal to invest in?
Marker Therapeutics, Inc. (MRKR) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.
Why did Marker Therapeutics, Inc. get a F compliance rating?
Marker Therapeutics, Inc. (MRKR) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.0% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change Marker Therapeutics, Inc.'s Shariah verdict?
Marker Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is Marker Therapeutics, Inc. re-screened for Shariah compliance?
Marker Therapeutics, Inc. (MRKR) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 26, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.